<DOC>
	<DOCNO>NCT02268747</DOCNO>
	<brief_summary>This open label , monocentric , uncontrolled phase II trial Dacomitinib , pan-HER inhibitor , unresectable metastatic skin SCC . HER2 expression common skin SCC , report high rate , even small study . Coexpression EGFR , HER2 HER3 present skin SCCs normal skin could associate malignant phenotype . In frame Dacomitinib could play role increase response rate .</brief_summary>
	<brief_title>Efficacy Safety Dacomitinib Treatment Skin Squamous Cell Cancer</brief_title>
	<detailed_description>The patient assume Dacomitinib 30 mg daily first 2 week . If high skin toxicity grade &lt; 2 , patient start dacomitinib 45 mg daily clinically assess every cycle ( i.e . every 28 day ) . If high skin toxicity grade &gt; 2 , patient interrupt treatment follow criterion dose reduction . Tumor evaluation perform baseline every cycle . Response assess accord RECIST 1.1 . The patient continue assume study drug disease progression , unacceptable toxicity medical condition suggest stop treatment patient 's safety</detailed_description>
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<criteria>Signed informed consent treatment Histological diagnosis squamous cell carcinoma skin amenable surgical treatment curative purpose clinical contraindication surgery ( examples medical contraindication surgery include limit : skin SCC recur location two surgical procedure curative resection deem unlikely ; anticipate substantial morbidity and/or deformity surgery ( e.g. , removal part facial structure , nose , ear , eyelid , eye ; requirement limb amputation ) ; anticipate difficulty obtain curative resection due location tumour , size disease ; anticipate difficulty reconstruct area surgically remove ; significant comorbidities preclude feasibility radical surgery Presence measurable disease accord RECIST 1.1 ECOG performance status 02 Ageâ‰¥ 18 year For men woman fertile period : use birth control system treatment Previous treatment tyrosine kinase inhibitor monoclonal antibody direct EGFR Any toxicity CTC grade &gt; 2 previous treatment yet resolve Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>skin squamous cell cancer panHER inhibitor Dacomitinib</keyword>
</DOC>